The current tumor staging system is insufficient for predicting the outcomes of patients with colorectal cancer (CRC) because of its phenotypic and genomic heterogeneity. Integrating gene expression signatures with clinicopathological factors may yield a predictive accuracy exceeding that of the currently available system. Twenty-seven signatures that used gene expression data to predict CRC prognosis were identified and re-analyzed using bioinformatic methods. Next, clinically annotated CRC samples (n=1710) Implications: These findings offer evidence that genomic data provides independent and complementary prognostic information, and incorporation of this information refines the prognosis of CRC.
for recurrence have already occurred in the primary CRC, providing the possibility to develop robust prognostic tools by using multiple genes in combination (6) . During the last decade, gene signatures have shown great promise in predicting the long-term outcomes and treatment responses of individual patients (7) . Of note, because of the outstanding ability to predict the prognoses of patients with breast cancer, multigene assays, such as Oncotype DX and MammaPrint, have been successfully approved by the US Food and Drug Administration and are available in routine clinical practice (8) .
Actually, genomic signatures to predict the prognosis of CRC have also been continually developed in the past 10 years, but none are commercially used in the clinic (9) . For example, Agesen et al. established a 13-gene expression classifier, ColoGuideEx, for prognosis predictions specific to patients with stage II CRC (10) .
Based on the essential role of lipid metabolism in carcinogenesis, Teodoro et al. reported. Therefore, investigating the predictive ability of these published signatures on comprehensive large-scale datasets and identifying whether any can be used to clinically guide treatment decisions is necessary.
Currently, while doubts about the predictive value of clinicopathological features are increasing, they still provide the most reliable guidelines for the prognostication and treatment of CRC (16). Thus, we hypothesized that integrating genomic signatures with clinicopathological features in a model would yield a predictive accuracy exceeding that of the currently available prognostic system. Nomogram is a statistical prediction model that combines multiple prognostic factors to make intuitive graphical and individualized predictions (17). Here, we aimed to apply a systematic approach to evaluate the clinical usefulness of CRC-related signatures and then construct a composite clinicopathologic-genomic nomogram by integrating factors with potential prognostic value in a training set. Moreover, using another independent set, the capacity of the nomogram to stratify CRC patients most likely to benefit from chemotherapy was further validated.
Materials and Methods

Patients and prognostic signatures
To identify gene expression data arrayed using the Affymetrix platform with clinically annotated data, we systematically searched Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/), ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) and related literature with the keywords "colorectal cancer ", "CRC", "colon cancer ", "survival", "relapse", "recurrence", "prognostic", "prognosis" and "outcomes" published through Aug 1, 2017. For some datasets whose clinical data did not accompany their gene expression profiles, we either searched the supplements or contacted one or more of the investigators to obtain the missing information.
Moreover, datasets with small sample sizes and duplications were excluded. Raw microarray data and the corresponding clinical data of these datasets were retrieved and manually organized when available. Only patients diagnosed with colorectal cancer having clinicopathological and survival information available were included.
Patients with follow-up or survival times of less than 1 month as well as patients with missing or insufficient data on age, local invasion, lymph node metastasis, distant metastasis and TNM stage were excluded from subsequent processing. Eventually, all patients satisfying the inclusion criteria were combined and summarized in Supplementary Table S1 and S2.
Expression data processing
For raw CEL files available from Affymetrix microarrays, the data were normalized and annotated using a MAS5 algorithm and the corresponding annotation files from R Bioconductor to obtain summarized values for each probeset; otherwise, pre-processed data as provided by the contributors were used. For each sample in every data set, measurements without a gene annotation were excluded, and multiple probesets corresponding to a single gene were summarized into a gene symbol by taking the most variable probeset measured by the interquartile range (IQR).
Identification and analysis of gene signatures potentially related to CRC prognosis
Gene signatures potentially related to CRC prognosis were systematically retrieved from PubMed. The search was restricted to recent papers to increase validity (from January 2004 to August 2017). The selection criteria are detailed in Supplementary Figure S1 . Articles that provided a list of differentially expressed genes in primary tumor samples associated with CRC prognosis were included in our study. Studies based on tissue microarray and those that were exclusively focused on differences between stages or between primary tumors and metastases were excluded. The signatures finally included in our analysis are described in Table 1 (detailed   descriptions provided in Supplementary Table S3 ). In addition, the probesets or genes of those signatures were re-annotated using the SOURCE web tool to address the retired gene symbols and their differences in the tested platforms. The re-annotated genes were then subjected to biological function enrichment analysis, and the online analytical tool DAVID (Database for Annotation, Visualization and Integrated Discovery) (18) was used to enrich gene ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. GO terms and KEGG pathways with significant enrichment false discovery rate (FDR) values less than 0.05 were selected for further analysis. In addition, genes from the abovementioned signatures were mapped and imported into the Retrieval of Interacting Genes/Proteins (STRING) 9.1 database, which queried the human protein-protein interaction network for interactions between effective linkers and seeds to construct a functional subnetwork. Cluster analyses were performed using correlation distance metrics and the average linkage agglomeration algorithm (R package nclust version 1.9.0; ref. 34 ).
Non-negative matrix factorization (NMF) was done with the NMF package (version 0.20.5) and standard strategies. 
Subclass prediction of CRC patients in the training set
The re-preprocessed microarray dataset, which represents the genomic features of the individual, were classified with the prognostic signatures identified above using the nearest template prediction (NTP) method (19) as implemented in Gene Pattern software (Broad Institute of Harvard and MIT, Boston, MA) (20) . NTP requires only a list of pre-specified template signature genes and a dataset to be tested and not a corresponding training dataset to capture good and poor gene expression patterns in 
Development, comparison, and validation of the prognostic models
All the patients included in this study were randomly separated into training and validation sets. Disease-free survival (DFS) was defined as the interval between the day that surgery was performed and the day that recurrence was first detected. If recurrence was not diagnosed, the date of death due to CRC or last follow-up was used. Overall survival (OS) was calculated from the date of diagnosis or surgery to the date of death or last follow-up. Continuous variables were expressed as median (IQR) (22) . In the training set, survival curves for different variable values were generated using Kaplan-Meier estimates and compared using the log-rank test.
Variables that achieved significance at p values less than 0.05 were subjected to multivariate analyses via the Cox regression model. Then, statistical analyses to identify independent prognostic factors were conducted. Based on the multivariate analysis results, a prognostic nomogram was established using a backward stepwise Cox proportional hazard model. The entire population was divided into three risk groups (high, intermediate, low) according to the tertiles of the total scores given by the established nomogram in the training set. Concordance index (c-index) values were used to measure the discrimination performance. Finally, for external validation, the total scores of each patient in the validation set were calculated according to the proposed nomogram to verify its generalization. Three risk groups were determined by the tertiles defined in the training set, and the respective Kaplan-Meier survival curves were delineated. All statistical tests performed were two-sided, and p values less than 0.05 were considered statistically significant.
Results
Screening and analysis of eligible samples and published signatures
To comprehensively evaluate their clinical usefulness, we retrieved all of the Figure S2D) , suggesting that patients from different cohorts in the present study could be blended together. Moreover, to balance the baseline characteristics, all eligible patients were randomly divided into a training set (n = 855) and a validation set (n = 855). The demographic and major clinicopathological characteristics of the patients are summarized in Supplementary Table S2 . As we expected, no significant differences were observed between the statistical properties of the training and validation sets.
Global prognostic performance of the published signatures
To determine the correlations of signatures and CRC patient outcomes, the prognostic performances of the 27 signatures were evaluated in the training set using a modified NTP method as previously described (19) . Among the 27 signatures evaluated, all except one (Teodoro's (24) signature had the only poor prognostic gene) were able to confidently stratify patients (FDR <0.05) into good and poor subgroups. Table 1 and Figure 2A summarize the prediction results obtained for each of the 855 patients.
Popovici's signature [34] was the most prevalent prediction in the training set (83.6%; 615 of 855), whereas Agesen's signature [42] was securely identified in only 19.9%
(167 of 855) of CRC patients. Of note, conflicting prognostic outcomes were commonly observed among the training set, and only 34% patients had consistent results (good or poor prognosis) in more than 5 signatures. However, as demonstrated in Figure 2A , the overall tendency of the NTP analysis was consistent and roughly consistent with previous studies (25) . In addition, global Cramer's V coefficients were calculated for each signature to gain insight into their concordances. Unsupervised clustering based on these coefficients indicated a substantial association among these signatures ( Figure 2B 
Validating the nomogram for stratifying CRC patient risks
To validate the correlation between the nomogram score (total points) and DFS statuses of patients with CRC, Kaplan-Meier analysis and log-rank tests based on the same cutoff value were conducted on the validation set. As shown in Figure 4A and B, applying the clinicopathologic-genomic nomogram stratified patients into three distinct risk subgroups with significantly different DFS rates. In addition, the prognostic accuracy of the nomogram was remarkably better than those of both clinicopathological and genomic information by themselves ( Figure 4C Considering the inherent deficiency of TNM stages, substantial effort has been placed on their optimization (2), and they have been continuously developed over the past decade. Substantial changes in CRC classifications, based mainly on the analysis of surveillance, epidemiology, and end results (SEER) data, were made in the seventh edition (34) . However, a comparative study demonstrated that the seventh TNM edition did not provide a greater accuracy for predicting CRC patient prognoses but rather resulted in a more complex classification for daily clinical use (35) . The eighth edition of the CRC staging system, containing major advances, including the introduction of molecular markers, such as MSI, KRAS and BRAF mutations, to strengthen its discriminatory power, will be implemented worldwide on January 1, 2018 (2). Nonetheless, the forthcoming edition may not provide substantial improvement because the prognostic value of clinicopathological factors has peaked. Moreover, the current models still lack genomic information, which may directly reflect the heterogeneity of CRC and present substantial potential prognostic value. average expression levels of ISC genes had a relative risk of relapse that was 10-fold higher than that for patients with low levels (23) . Moreover, recent evidence (37) suggest that gene signatures that closely reflect specific biological processes or oncogenic pathway statuses also have potential prognostic values for stratifying CRC patients. Even though almost all of these signatures were proven to have prognostic value in their respective publications, none are routinely used in clinical practice.
Potential explanations for the unsatisfactory results must be considered. Thus, in the current study, we exhaustively reviewed and analyzed the published multi-gene signatures in CRC. To eliminate the potential confounding effects, only data derived from the Affymetrix human genome platform having clearly described genes were included. Of the 81 published signatures, 27 signatures from 26 publications met all of the inclusion criteria and were retained (Table 1 and Supplementary Table S3 ). The 27 signatures contained 1274 total genes, among which 1041 were unique, and the signature sizes ranged from 4 to 264 ( Figure 1A) . The top overlapping genes in the above signatures were FN1 (ten times), CYP1B1 and POSTN (six times), 7 genes (five times), 7 genes (four times), 29 genes (three times), and 107 genes (twice). As is clearly shown in Figure 2A , none of these genes appeared in all signatures. These results were expected since they were previously reported (15) and in agreement with the systematic analyses of lung cancer and breast cancer prognostic signatures (38) .
Obviously, the slight overlap of these signatures in gene identity was perplexing but sufficiently explained the low reproducibility. Moreover, genetic heterogeneity was recently shown to exist not only between but also within tumors, meaning that biological statuses, including oncogenic and carcinostatic states, might regularly vary in the same patient (39) . Our NTP analysis revealed that some patients concurrently 
harbored more than one signature, which further confirmed the abovementioned results and indicated that their tumors were genomic instability at the individual level.
Taken together, the different signatures might reflect diverse biological processes and be active in different or identical individual tumors, which partially accounts for the wide nonoverlapping among signatures constructed in different CRC studies.
In terms of global performance, in the training set, 8 of 27 signatures showed a significant association with prognosis and could reasonably predict the outcome.
However, after multivariate adjustment, only 2 signatures remained powerful enough to indicate prognosis for DFS, which directly demonstrated the low reproducibility of CRC genomic signatures. More importantly, Popovici's signature, Fritzmann's signature and TNM stage had remarkable prognostic abilities and were independent of each other, indicating that these signatures may be used to refine the current prognostic model and facilitate further stratification of patients with CRC at the same TNM stage.
Our primary goal was to construct a nomogram that could integrate genomic signatures with clinicopathological variables in a large cohort of CRC patients to add additional prognostic value to the current staging system. Our multivariate analysis in the training set revealed that age, local invasion, lymph node metastasis, distant metastasis, TNM stage, Popovici's signature and Fritzmann's signature were independent prognostic factors (Supplementary Table S6), which was highly consistent with previous studies on CRC risk factors (40, 41) . Accordingly, we cautiously built a clinicopathologic-genomic nomogram using the abovementioned significant factors. The AUC of the nomogram showed a superior prediction accuracy compared to that of the combined clinical factors in the training and validation sets ( Figure 3E, 4C) . Additionally, the calibration plots showed optimal agreement between the expected and observed survival probabilities ( Figure 3B ), ensuring the reliability of our nomogram. Moreover, the nomogram successfully stratified CRC patients into three risk groups with remarkably different DFS values based on total points, which was further confirmed using the same cutoff value in the validation set.
Intriguingly, the TNM staging system is the most important tool for guiding (Figure 5 ).
Despite the promising results, there were several shortcomings in this work. First, the NTP method uses only a list of signature genes to make class predictions in each patient's expression data, allowing the method to be less sensitive to differences in experimental and analytical conditions and applicable to every patient without optimization of the analysis parameters. In the current study, we applied the NTP method for all prediction models, which generally consisted of two major components: a gene signature and a prediction algorithm. Obviously, the intrinsic limitation of the NTP method is that it inevitably causes the algorithm lose its prognostic value.
Second, the forthcoming 8th edition of the CRC TNM staging system may better predict prognosis, but data used in the present study was from the current 7th edition or the 6th edition. Third, the prognostic signatures of CRC included in our study were not exhaustive, and some promising signatures were excluded because of insufficient information. In addition, some clinicopathological factors, even those well recognized to have prognostic value, were not included in the composite nomogram because of the low availability of information.
In summary, based on analyzing a large-scale CRC cohort and published multi-gene prognostic signatures, we confirmed herein for the first time that genomic information in combination with clinical data can improve patient prognostic evaluations and should be considered as an independent and complementary approach to the current clinicopathological prognostic model. Furthermore, considering the wide promise of our nomogram, which integrates genomic signatures with clinicopathological features to improve the prognosis prediction of colorectal cancer, 
